A Phase 2 interventional study of MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline and MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline in Anemia and Chronic Kidney Disease, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 82nd largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2009, is one of 44 in phase 2, and was the 105th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 7 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating agents.
This study consists of a 12-week base study (MK2578-003-AM03) and an optional 40-week extension study (MK2578-003-EXT12). Participants who complete 12 weeks of treatment in the base study will enter the extension on the most recent dose administered in the base study or a newly adjusted dose, if adjustment is required to bring Hg levels within range. Participants' doses of MK2578 will be adjusted upward or downward during the extension study to maintain Hb in the range of 10-12 g/dL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Base Study:
Extension Study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive treatment every week (QW).
Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Participants were randomized to receive treatment QM.
Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Participants were randomized to receive treatment QW.
Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Participants were randomized to receive treatment QM.
Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Participants were randomized to receive treatment QW.
Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
Participants were randomized to receive treatment QM.
Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Change From Baseline in Hemoglobin (Hg) Level at Week 4
Time frame: 4 weeks
Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)
Time frame: 12 weeks
Number of Participants With Composite Events of Transfusion-Related Adverse Experiences
Time frame: 12 weeks
Number of Participants With Composite Events of Infusion Reactions
Time frame: 12 weeks
Number of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia
Time frame: 12 weeks
Number of Participants With Confirmed, Treatment Emergent Antibodies to MK2578
Time frame: 12 weeks
Change From Baseline in Hg Level at Week 12
Time frame: 12 weeks
Participants were recruited from 46 centers (9 centers in Bulgaria, 27 in United States, 3 in Romania, 4 in Italy, and 3 in Poland).
| Milestone | MK2578 1mcg/600 U or 1 mcg/350 U QW | MK2578 1mcg/600 U or 1 mg/350 U QM |
|---|---|---|
| Started | 20 | 19 |
| Completed | 8 | 9 |
| Not completed | 12 | 10 |
| Withdrew: Study terminated by sponsor | 12 | 10 |
| g/dL | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin (Hg) Level at Week 4 | -0.6 ± 0.8 | -0.7 ± 1.0 | -1.0 ± NA | -1.0 ± NA |
| Participants | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM |
|---|---|---|---|---|
| Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA) | 0 | 1 | 0 | 0 |
| Participants | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM |
|---|---|---|---|---|
| Number of Participants With Composite Events of Transfusion-Related Adverse Experiences | 0 | 0 | 0 | 0 |
| Participants | MK2578 1mcg/600U QW | MK2578 1mcg/600 QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM |
|---|---|---|---|---|
| Number of Participants With Composite Events of Infusion Reactions | 0 | 0 | 0 | 0 |
| Participants | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM |
|---|---|---|---|---|
| Death | 0 | 0 | 0 | 0 |
| MI | 0 | 1 | 0 | 0 |
| CVA | 0 | 0 | 0 | 0 |
| Peripheral vascular thromboses | 0 | 0 | 0 | 0 |
| Vascular access thrombosis | 0 | 0 | 1 | 0 |
| CHF | 0 | 0 | 0 | 0 |
| Hypertension | 1 | 1 | 0 | 0 |
| Seizure | 0 | 0 | 0 | 0 |
| Pure red cell aplasia | 0 | 0 | 0 | 0 |
No measurements were reported for this outcome.
| g/dL | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK-2578 1mcg/350U QM |
|---|---|---|---|---|
| Change From Baseline in Hg Level at Week 12 | -0.1 ± 1.4 | -0.5 ± 1.4 | — | — |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK2578 QW | — | 1/20 (5%) | 9/20 (45%) |
| MK2578 QM | — | 2/19 (10.5%) | 7/19 (36.8%) |
| Event | MK2578 QW | MK2578 QM |
|---|---|---|
| Acute mycoardial infarctionCardiac disorders | 0/20 | 1/19 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 0/20 | 1/19 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/20 | 1/19 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/20 | 0/19 |
| Event | MK2578 QW | MK2578 QM |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/20 | 1/19 |
| Adrenal cystEndocrine disorders | 0/20 | 1/19 |
| Abdominal distentionGastrointestinal disorders | 0/20 | 1/19 |
| GastritisGastrointestinal disorders | 0/20 | 1/19 |
| NauseaGastrointestinal disorders | 0/20 | 1/19 |
| OesophagitisGastrointestinal disorders | 0/20 | 1/19 |
| AstheniaGeneral disorders | 0/20 | 1/19 |
| Non-cardiac chest painGeneral disorders | 0/20 | 1/19 |
| Oedema peripheralGeneral disorders | 0/20 | 1/19 |
| Bacterial disease carrierInfections and infestations | 0/20 | 1/19 |
| Age, Continuous(years) | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM | Total |
|---|---|---|---|---|---|
| Mean | 46.3 ± 14.29 | 51.7 ± 10.22 | 58.0 ± 8.91 | 60.5 ± 4.51 | 51.0 ± 12.30 |
| Sex: Female, Male(Participants) | MK2578 1mcg/600U QW | MK2578 1mcg/600U QM | MK2578 1mcg/350U QW | MK2578 1mcg/350U QM | Total |
|---|---|---|---|---|---|
| Female | 10 | 8 | 3 | 3 | 24 |
| Male | 6 | 7 | 1 | 1 | 15 |
No study locations are listed for this record.
The record gives a start of Jun 2009, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa